Literature DB >> 20170711

Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence.

Falk W Lohoff1, Paul J Bloch, Rachel Hodge, Aleksandra H Nall, Thomas N Ferraro, Kyle M Kampman, Charles A Dackis, Charles P O'Brien, Helen M Pettinati, David W Oslin.   

Abstract

Genetic research on cocaine dependence (CD) may help clarify our understanding of the disorder as well as provide novel insights for effective treatment. Since dopamine neurotransmission has been shown to be involved in drug reward, related genes are plausible candidates for susceptibility to CD. The dopamine receptor D(2) (DRD2) protein and dopamine transporter (DAT1) protein play regulatory roles in dopamine neurotransmission. The TaqI A single-nucleotide polymorphism (SNP) in the DRD2 gene and the 3' variable number tandem repeat (VNTR) polymorphism in the DAT1 gene have been implicated in psychiatric disorders and drug addictions. In this study, we hypothesize that these polymorphisms contribute to increased risk for CD. Cocaine-dependent individuals (n=347) and unaffected controls (n=257) of African descent were genotyped for the polymorphisms in the DRD2 and DAT1 genes. We observed no statistically significant differences or trends in allele or genotype frequencies between cases and controls for either of the tested polymorphisms. Our study suggests that there is no association between the DRD2 and DAT1 polymorphisms and CD. However, additional studies using larger sample sizes and clinically homogenous populations are necessary before confidently excluding these variants as contributing genetic risk factors for CD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170711     DOI: 10.1016/j.neulet.2010.02.021

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.

Authors:  Toni-Kim Clarke; Amy R D Weiss; Thomas N Ferarro; Kyle M Kampman; Charles A Dackis; Helen M Pettinati; Charles P O'brien; David W Oslin; Falk W Lohoff; Wade H Berrettini
Journal:  Ann Hum Genet       Date:  2013-11-25       Impact factor: 1.670

Review 2.  Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment.

Authors:  Sarah W Yip; Marc N Potenza
Journal:  Clin Psychol Rev       Date:  2016-11-09

3.  Dopamine Transporter Gene Methylation is Associated with Nucleus Accumbens Activation During Reward Processing in Healthy but not Alcohol-Dependent Individuals.

Authors:  Christine Muench; Corinde E Wiers; Carlos R Cortes; Reza Momenan; Falk W Lohoff
Journal:  Alcohol Clin Exp Res       Date:  2017-11-27       Impact factor: 3.455

4.  HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations.

Authors:  Michelle M Jacobs; Jacinta Murray; Desiree A Byrd; Yasmin L Hurd; Susan Morgello
Journal:  J Neurovirol       Date:  2013-10       Impact factor: 2.643

5.  Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.

Authors:  June P Kampangkaew; Catherine J Spellicy; Ellen M Nielsen; Mark J Harding; An Ye; Sara C Hamon; Thomas R Kosten; David A Nielsen
Journal:  Am J Addict       Date:  2019-05-14

6.  Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects.

Authors:  Yanhong Zhou; Sharon K Michelhaugh; Carl J Schmidt; Jun S Liu; Michael J Bannon; Zhicheng Lin
Journal:  Addict Biol       Date:  2011-10-26       Impact factor: 4.280

7.  Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.

Authors:  Kenneth Blum; Amanda L C Chen; Marlene Oscar-Berman; Thomas J H Chen; Joel Lubar; Nancy White; Judith Lubar; Abdalla Bowirrat; Eric Braverman; John Schoolfield; Roger L Waite; Bernard W Downs; Margaret Madigan; David E Comings; Caroline Davis; Mallory M Kerner; Jennifer Knopf; Tomas Palomo; John J Giordano; Siobhan A Morse; Frank Fornari; Debmalya Barh; John Femino; John A Bailey
Journal:  Int J Environ Res Public Health       Date:  2011-11-29       Impact factor: 3.390

8.  Butyrylcholinesterase genetic variants: association with cocaine dependence and related phenotypes.

Authors:  André Brooking Negrão; Alexandre Costa Pereira; Camila Guindalini; Hadassa Campos Santos; Guilherme Peres Messas; Ronaldo Laranjeira; Homero Vallada
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

9.  Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability.

Authors:  E Shumay; J S Fowler; G-J Wang; J Logan; N Alia-Klein; R Z Goldstein; T Maloney; C Wong; N D Volkow
Journal:  Transl Psychiatry       Date:  2012-03-06       Impact factor: 6.222

10.  Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine.

Authors:  Carlos Isaza; Julieta Henao; Leonardo Beltrán; Liliana Porras; Martha Gonzalez; Raquel Cruz; Angel Carracedo
Journal:  Colomb Med (Cali)       Date:  2013-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.